Researchers conducted a randomized controlled trial involving 98 patients with schizophrenia who had previously taken olanzapine. These participants were switched to either cariprazine or aripiprazole for a period of 12 weeks at a tertiary care center. The study aimed to compare how these two medications affected body weight and other metabolic health markers.
The results showed a significant interaction between treatment type and time regarding body weight. Specifically, patients taking cariprazine experienced a modestly greater reduction in weight compared to those on aripiprazole. The average difference in weight loss was 0.82 kilograms. Both groups also saw improvements in various health measures within themselves over the study period.
However, the study authors note that the magnitude of the weight difference was small. They caution that these findings should be interpreted carefully and suggest that larger, multicenter studies with longer follow-up are needed to confirm these results. No serious adverse events or discontinuations were reported during the trial. Readers should understand that while a potential metabolic advantage exists, it is not a guaranteed outcome and requires further verification before changing treatment plans.
